SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Swami who wrote (448)12/21/1998 5:26:00 PM
From: w sun  Read Replies (2) of 1084
 
As pointed out in the article cited in poster #445(please see #436, #371 too), CellPro's stem cell selector got FDA back in 1996 and seem full of hope. Two years later this summer it's liquidated and does not exist any more. Look at the others referred in that article, Baxter, RPR, and Amgen, They are all much bigger, and richer too. That's the risk in little bio companies. One has to say it's very fortunate that astm has survived till today. Even the company itself said recently that its capital may support its operation up to middle of 1999. What's after? That's the kind of risk one is facing.

Replicell and stem cell kits may be great technology(But the Cobe's pull-out and comments are worry-some). What's revenue potential? What's gross-margin(system and kits)? Time and money are running out. To succeed, astm needs a bigger partner, astm needs a buy-out!(ws)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News